Recently published NICE guidance recommends the use of UrgoStart on Venous Leg Ulcers and Diabetic Foot Ulcers(1)

UrgoStart dressings are proven to reduce healing time for patients, improving patients' quality of life, and are associated with significant cost savings for the NHS compared to non-interactive dressings.

What does the NICE medical technology guidance say about UrgoStart Treatment Range?
Reduces healing time 

UrgoStart Treatment Range heals wounds sooner

UrgoStart is clinically proven to reduce healing time through the highest level of evidence (2-5)
UrgoStart with its TLC-NOSF* Healing Matrix has a unique mode of action to reduce healing time: inhibition of matrix metalloproteinases and promotion of angiogenesis (5,6)

Saves costs

£342 per patient per year for diabetic foot ulcers(1)

£541 per patient per year for leg ulcers**(1)

Reducing healing time can save money through:

  • Reduced use of current dressings in managing wounds

  • Reduced risk of infection and associated complications

  • Fewer community nursing and hospital visits

Easy to implement 

UrgoStart can be easily incorporated into current care pathways as part of the standard of care

UrgoStart treatment range does not require any specific training to be used in clinical practice

Enhances quality of life 

UrgoStart improves the quality of life for patients

Reducing healing time with UrgoStart significantly reduces pain/discomfort and anxiety/depression (4)

** Results from the NICE External Assessment Centre (EAC) base case analysis


  1. NICE medical technology guidance 42: UrgoStart for treating diabetic foot ulcers and leg ulcers,; accessed August 2019

  2. Münter KC, Meaume S, Augustin M, Senet P, Kérihuel J.C. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care. 2017 Feb; 26 (Sup2): S4-S15. Erratum in: J Wound Care. 2017 Mar 2; 26(3): 153

  3. Meaume S, Truchetet F, Cambazard F et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen. 2012; 20: 4, 500–511.

  4. Meaume S, Dompmartin A, Lazareth I, Sigal M, Truchetet F, Sauvadet A, Bohbot S. Quality of life in patients with leg ulcers: results from CHALLENGE, a double-blind randomized controlled trial. Journal of Wound Care. 2017; 26 (7): 368-379.

  5. Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196.

  6. White, R., Cowan, T., Glover, D. Supporting evidence-based practice: a clinical review of TLC healing matrix (2nd edition). MA Healthcare Ltd, London, 2015.